What is the dosage of Prozac (fluoxetine) for an adult with depression or anxiety?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 2, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Prozac (Fluoxetine) Dosing for Depression and Anxiety

Standard Adult Dosing

Start fluoxetine at 20 mg once daily in the morning for most adults with depression or anxiety. 1 This is the FDA-approved initial dose and is sufficient to obtain a satisfactory response in major depressive disorder in most cases. 1

Initial Dosing Strategy

  • For patients with prominent anxiety symptoms or panic disorder, consider starting at 10 mg daily (or even 5 mg daily) for the first week before increasing to 20 mg daily. 2 Approximately 28% of patients cannot tolerate the full 20 mg dose initially, with half of these patients doing well clinically on lower doses. 2

  • Morning dosing is strongly preferred because fluoxetine is activating and may cause insomnia if taken later in the day. 3

Dose Titration

  • If insufficient clinical improvement occurs after several weeks at 20 mg daily, increase the dose in increments. 1 The FDA label supports doses up to 80 mg/day for depression and anxiety disorders. 1

  • For OCD specifically, higher doses (60-80 mg daily) demonstrate superior efficacy compared to lower doses and are often necessary. 4

  • Allow 4 weeks or longer for full therapeutic effect before concluding treatment failure. 1

Dosing Schedules

  • Doses above 20 mg/day may be administered once daily (morning) or twice daily (morning and noon). 1

  • Maximum dose should not exceed 80 mg/day. 1

Special Populations

Elderly Patients

Use lower or less frequent dosing in elderly patients—approximately 50% of the standard adult starting dose. 3 Older adults are at significantly greater risk of adverse drug reactions. 3

Hepatic Impairment

A lower or less frequent dosage should be used in patients with hepatic impairment. 1

CYP2D6 Poor Metabolizers

CYP2D6 poor metabolizers should start at 10 mg daily with cautious titration due to 3.9 to 11.5-fold higher fluoxetine levels and significantly increased toxicity risk, including QT prolongation. 3 The FDA has issued safety warnings about this risk. 3

Pediatric Dosing (Children and Adolescents)

Start with 10 mg daily for one week, then increase to 20 mg daily. 1 In lower weight children, the starting and target dose may remain at 10 mg/day, with dose increases to 20 mg considered after several weeks if insufficient improvement occurs. 1

Treatment Duration

Continue fluoxetine for 4-9 months minimum after satisfactory response for first-episode depression. 4 For patients with recurrent episodes, consider longer duration of ≥1 year or indefinite maintenance therapy. 4

Critical Safety Monitoring

  • Monitor closely for treatment-emergent suicidality, particularly in the first 1-2 weeks after initiation or dose changes, especially in patients under age 24. 4 All SSRIs carry FDA black box warnings for increased suicidality risk. 4

  • Fluoxetine has an exceptionally long half-life (1-3 days for parent compound, 4-16 days for active metabolite norfluoxetine), meaning steady-state is not reached until approximately 5-7 weeks after a dose change. 3 Side effects may not manifest for several weeks. 3

Common Pitfalls to Avoid

  • Do not discontinue prematurely—full response may take 6-8 weeks, and approximately 38% of patients do not achieve response during initial 6-12 weeks. 4

  • Do not combine with MAOIs due to serotonin syndrome risk. Allow at least 14 days after stopping an MAOI before starting fluoxetine, and at least 5 weeks after stopping fluoxetine before starting an MAOI. 1

  • Fluoxetine strongly inhibits CYP2D6 and can cause dangerous interactions with tamoxifen, codeine, tramadol, and other CYP2D6 substrates. 4

  • Gradual tapering is recommended when discontinuing, although fluoxetine has the lowest risk of discontinuation syndrome among SSRIs due to its long half-life. 4

Comparative Efficacy

Fluoxetine demonstrates equivalent efficacy to other SSRIs (sertraline, paroxetine, escitalopram, citalopram) for treating depression and anxiety. 4 However, venlafaxine may have statistically better response rates than fluoxetine specifically for depression with prominent anxiety symptoms. 4

Fluoxetine is effective in treating major depression with comorbid anxiety disorders, with significant effects on both depression and anxiety symptoms. 5, 6, 7 In one study, 53% of patients with depression and comorbid anxiety disorders were responders (≥50% decrease in depression scores) after 8 weeks of fluoxetine 20 mg daily. 5

References

Research

Use of low-dose fluoxetine in major depression and panic disorder.

The Journal of clinical psychiatry, 1993

Guideline

Management of Increased Anxiety After Fluoxetine Dose Increase

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Serotonin Modulators for Depression and Anxiety

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Research

Fluoxetine treatment of depressed patients with comorbid anxiety disorders.

Journal of psychopharmacology (Oxford, England), 2002

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.